Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
25.77
-0.37 (-1.42%)
Jul 1, 2026, 3:54 PM EDT - Market open
Zymeworks Revenue
Zymeworks had revenue of $2.41M in the quarter ending March 31, 2026, a decrease of -91.12%. This brings the company's revenue in the last twelve months to $81.26M, down -12.98% year-over-year. In the year 2025, Zymeworks had annual revenue of $105.97M with 38.87% growth.
Revenue (ttm)
$81.26M
Revenue Growth
-12.98%
P/S Ratio
22.95
Revenue / Employee
$334,416
Employees
243
Market Cap
1.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.97M | 29.66M | 38.87% |
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
| Dec 31, 2018 | 53.02M | 1.26M | 2.43% |
| Dec 31, 2017 | 51.76M | 40.75M | 370.18% |
| Dec 31, 2016 | 11.01M | 1.35M | 13.96% |
| Dec 31, 2015 | 9.66M | 7.99M | 478.44% |
| Dec 31, 2014 | 1.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| ADMA Biologics | 509.86M |
| Iovance Biotherapeutics | 285.61M |
| AnaptysBio | 232.39M |
| Syndax Pharmaceuticals | 217.17M |
| Recursion Pharmaceuticals | 66.41M |
| Nanobiotix | 38.27M |
| AtaiBeckley | 3.49M |
ZYME News
- 1 day ago - Zymeworks price target raised to $37 from $34 at Wells Fargo - TheFly
- 1 day ago - Zymeworks price target raised to $37 from $35 at Citi - TheFly
- 2 days ago - Zymeworks Transcript: M&A announcement - Transcripts
- 2 days ago - Zymeworks Press release: M&A announcement - Filings
- 2 days ago - Zymeworks Slides: M&A announcement - Filings
- 2 days ago - M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B - TipRanks
- 2 days ago - Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash - TheFly
- 2 days ago - Zymeworks strikes $929 million deal for Theravance Biopharma - Reuters